Altimmune announced that it has raised $14 million in a registered direct offering, with net proceeds of about $12.7 million. The company also said that an extension of a Phase 2 study of its NasoVax intranasal flu vaccine found that subjects were still protected against the flu more than a year after vaccination.
The company said that 8 subjects from the original study were tested, and all 8 retained seroprotection, with the same seroconversion rate, at an average 13 1/2 months after they were vaccinated. The 8 subjects had all received the highest dose of NasoVax evaluated in the study.
Altimmune President and CEO Vipin K. Garg said, “We are excited about the continued positive NasoVax results and believe that if approved, NasoVax has the potential to capture a significant portion of the global flu vaccine market. Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVax program.”
Read the Altimmune press release on the new funding.
Read the Altimmune press release on the study results.
